Klotz U, Antonin K H, Bieck P R
J Pharmacol Exp Ther. 1976 Oct;199(1):67-73.
The pharmacokinetics and plasma binding of diazepam were compared in man, dog, rabbit, guinea pig and rat. Diazepam (D) and its major metabolite, desmethyl-diazepam, were measured in blood and plasma by a specific and sensitive gas-liquid chromatography assay with an electron capture detector. After an intravenous bolus injection plasma levels of D declined biexponentially in all species examined and the data were analyzed according to the two-compartment open model. The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%). In man, the elimination half-life, T1/2(beta), increased significantly (P less than .01) with decreasing total plasma clearance (Cl). Plasma binding affected Vd and Cl, but only Cl increased significantly (P less than .05), if more free D was available. This indicates that unbound drug is rate-determining for clearance by the liver, and that D fits into the restrictive elimination class in man. In the four animal species tested, Cl was a direct linear function of the body surface area. T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species. A considerably higher extraction ratio than the unbound fraction of diazepam exists in these animal species, and blood clearance exceeds liver blood flow, giving reason to assume a much higher ability of the liver to metabolize D, and a species-dependent extrahepatic metabolism. The large variations described suggest that pharmacokinetic data or plasma binding results cannot simply be extrapolated to man.
对人、狗、兔、豚鼠和大鼠体内地西泮的药代动力学及血浆蛋白结合情况进行了比较。采用具有电子捕获检测器的特异性灵敏气液色谱分析法测定血液和血浆中的地西泮(D)及其主要代谢产物去甲基地西泮。静脉推注后,在所检测的所有物种中,D的血浆浓度均呈双指数下降,数据根据二室开放模型进行分析。通过平衡透析法测定了人(分别为96.8%和96.6%)、狗(96.0%和95.9%)、兔(89.9%和94.7%)、豚鼠(91.3%和78.6%)和大鼠(86.3%和90.5%)在治疗浓度下地西泮和去甲基地西泮的蛋白结合率。在人身上,消除半衰期T1/2(β)随总血浆清除率(Cl)的降低而显著增加(P<0.01)。血浆蛋白结合影响分布容积(Vd)和清除率(Cl),但只有当有更多游离D时,Cl才会显著增加(P<0.05)。这表明游离药物是肝脏清除率的限速因素,且地西泮在人体内属于限制性消除类型。在受试的四种动物物种中,Cl是体表面积的直接线性函数。T1/2(β)和药物清除率是每个物种的特征性数据:从大鼠的1.1小时和81.6毫升/分钟/千克到人的32.9小时和0.35毫升/分钟/千克,而分布半衰期T1/2(α)在不同物种中仅约有3倍的变化(0.3 - 1.0小时)。这些动物物种中地西泮的提取率远高于未结合部分,且血液清除率超过肝血流量,因此有理由认为肝脏代谢地西泮的能力更高,且存在物种依赖性的肝外代谢。所描述的巨大差异表明,药代动力学数据或血浆蛋白结合结果不能简单地外推至人体。